Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
ApexOnco Front Page
Recent articles
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
